BriaCell DSMB flags no safety issues, backs continued Phase 3 metastatic breast cancer trial of Bria-IMT plus checkpoint inhibitor
BCTX•BCTX•BCTX•BCTX•No new efficacy results were presented; the update focused on safety oversight rather than trial outcomes.
The review reported no safety concerns so far, supporting the program’s risk profile as enrollment and treatment continue.
The study runs under FDA Fast Track designation, positioning the asset for a potentially faster regulatory path if later data support it.
An independent safety board recommended continuing BriaCell’s Phase 3 Bria-ABC trial of Bria-IMT with an immune checkpoint inhibitor.
